Bruker (NASDAQ:BRKR) Price Target Lowered to $50.00 at Guggenheim

Bruker (NASDAQ:BRKR) had its price objective cut by Guggenheim from $58.00 to $50.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

BRKR has been the subject of a number of other reports. Jefferies Financial Group set a $50.00 target price on Bruker in a research report on Thursday, February 12th. Bank of America boosted their price objective on Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Citigroup cut their target price on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Wells Fargo & Company lifted their price objective on shares of Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, Bruker has an average rating of “Hold” and an average price target of $49.77.

Bruker Price Performance

Shares of NASDAQ:BRKR opened at $34.31 on Monday. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22. The firm has a market capitalization of $5.22 billion, a P/E ratio of -228.73, a P/E/G ratio of 2.02 and a beta of 1.19. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.73 and a quick ratio of 0.87. The company’s fifty day moving average price is $39.77 and its 200 day moving average price is $41.31.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The company had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The business’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be paid a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.6%. Bruker’s payout ratio is -133.33%.

Insiders Place Their Bets

In other Bruker news, VP Mark Munch sold 7,000 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the transaction, the vice president owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold a total of 11,000 shares of company stock worth $554,280 over the last quarter. Corporate insiders own 27.30% of the company’s stock.

Hedge Funds Weigh In On Bruker

A number of institutional investors and hedge funds have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC purchased a new stake in Bruker during the fourth quarter worth about $26,000. Allworth Financial LP boosted its stake in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. Parallel Advisors LLC grew its holdings in shares of Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the period. Spire Wealth Management increased its stake in Bruker by 85.3% in the 3rd quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in Bruker during the fourth quarter worth $50,000. 79.52% of the stock is owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.